Human-Centric AI platform for heALth and Life sciences

Abzu ApS an EU-based deep-tech start-up is redefining the AI landscape with an explainable, accurate and scalable solution the QLattice poised to disrupt the global AI race as the first truly responsible, trustworthy and transparent AI.

With EIC support and based on 15+ pharma pilots with second to none explainable and accurate insights, Abzu will develop Reason a tailor-made platform for pharma readily utilized by non-code savvy R&D scientists.

Current black box solutions lack user-friendliness and have failed to restrain steady R&D costs increases in the last 15-years (~2.5B per drug today).

Reason will reverse this trend with added value in key metrics of increased ROI, productivity, and treatment availability.

Abzus business, technology and the EUs strategic goals are at a unique crossroads of technological, societal and economic disruption.

EIC funds will make Abzu the next EU unicorn and result in the EU disrupting and gaining a foothold in the global AI market.